GO:0051378 serotonin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051378 serotonin binding is a molecular function defined as binding to serotonin (5-hydroxytryptamine), a monoamine neurotransmitter with peripheral and central nervous system roles and hormonal properties.
• Serotonin binding is mediated by multiple protein families, including serotonin receptors (HTR1-7), the serotonin transporter SLC6A4, vesicular monoamine transporter VMAT2 (SLC18A2), and soluble serotonin-binding proteins [3,4,6,7,8].
• The serotonin transporter SLC6A4 couples substrate binding to ion gradients, and a potassium-binding site has been identified that regulates its transport cycle [2,6].
• VMAT2 (SLC18A2) transports serotonin into synaptic vesicles using a proton gradient, and its transport and inhibition mechanisms have been resolved structurally.
• Serotonin binding underlies synaptic modulation relevant to addiction, chemoresistance, and neuropsychiatric disorders, as shown in cocaine addiction and ovarian cancer models [1,5].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of serotonin-binding proteins in disease and drug response.
Description
Serotonin binding (GO:0051378) is a molecular function that describes the selective interaction of a protein with serotonin (5-hydroxytryptamine), a monoamine neurotransmitter that acts in the peripheral and central nervous systems and also has hormonal properties. This function is fundamental to serotonergic signaling, as it initiates receptor activation, substrate translocation, or intracellular signaling cascades. The term encompasses binding events that are not necessarily coupled to catalysis, such as receptor-ligand recognition and transporter-substrate engagement [3,6]. Researchers study serotonin binding to understand synaptic transmission, mood regulation, and the pharmacological actions of serotonergic drugs [4,5]. The serotonin transporter SLC6A4 is a key example where substrate binding is coupled to ion gradients and conformational changes, and a potassium-binding site has been identified that modulates its function [2,6]. Additionally, vesicular monoamine transporter VMAT2 (SLC18A2) binds serotonin for packaging into synaptic vesicles, a process essential for neurotransmission. In the brain, soluble serotonin-binding proteins interact with serotonin and catecholamines, suggesting broader roles in monoamine homeostasis. Given its central role in neurobiology and emerging roles in cancer and immune regulation, serotonin binding is a critical target for basic and translational research [1,5].
serotonin binding At A Glance
| GO ID | GO:0051378 |
|---|---|
| GO term | serotonin binding |
| Ontology | molecular_function |
| Synonym | 5-hydroxytryptamine binding |
| Definition | Binding to serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties. |
| Major function | Mediates recognition and interaction with serotonin, enabling receptor activation, transporter-mediated uptake, or vesicular packaging. |
| Representative proteins | Serotonin receptors (HTR1-7), serotonin transporter SLC6A4, vesicular monoamine transporter SLC18A2 (VMAT2), and soluble serotonin-binding proteins. |
| Associated processes | Synaptic transmission, mood regulation, addiction, chemoresistance, and monoamine homeostasis. |
What Is GO:0051378?
According to the Gene Ontology, serotonin binding (GO:0051378) is the molecular function of binding to serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties. This term is used for proteins that selectively recognize and interact with serotonin, whether they are receptors, transporters, or intracellular binding proteins, without implying any downstream catalytic or signaling activity.
Why Is serotonin binding Important in Cell Biology?
Serotonin binding is essential for serotonergic neurotransmission and is a primary target of many therapeutic drugs, including antidepressants and antipsychotics. Dysregulation of serotonin binding proteins is implicated in neuropsychiatric disorders, addiction, and cancer progression [1,5]. Understanding the molecular details of serotonin binding, such as ion coupling in SLC6A4 and proton-dependent transport in VMAT2, provides a basis for drug design and mechanistic studies [2,6,7].
• Serotonin binding initiates signaling through serotonin receptors, which are targets for antidepressants, antipsychotics, and psychedelics.
• The serotonin transporter SLC6A4 is the primary target of selective serotonin reuptake inhibitors (SSRIs), and its binding mechanism is modulated by ions including potassium [2,6].
• VMAT2 (SLC18A2) binds serotonin for vesicular storage, and its dysfunction is linked to monoamine-related disorders.
• Serotonin binding in macrophages can potentiate chemoresistance in ovarian cancer via metabolic crosstalk.
• Synaptic serotonin binding modulates the transition to cocaine addiction, highlighting roles in reward circuitry.
• Soluble serotonin-binding proteins in the cerebral cortex interact with catecholamines, suggesting broader monoamine regulation.
• Serotonin binding sites are pharmacologically relevant for drug development targeting 5-HT receptors and transporters [3,4].
• Alterations in serotonin binding are associated with mood disorders, anxiety, and neurodegenerative conditions.
• CRISPR-based editing of genes encoding serotonin-binding proteins enables causal studies of their roles in health and disease.
• Serotonin binding research benefits from structural biology, as exemplified by the potassium-binding site in SLC6A4 and VMAT2 structures [2,7].
What Happens During serotonin binding?
Receptor recognition and activation
In simple terms: Serotonin binds to receptor proteins on the cell surface, like a key fitting a lock, to trigger signals inside the cell.
Serotonin receptors (HTR1-7) are G protein-coupled receptors or ligand-gated ion channels that bind serotonin with high specificity. This binding induces conformational changes that activate downstream signaling pathways, such as cAMP modulation or calcium release. The binding properties of serotonin receptors, including the 5-HT2 subclass, have been characterized pharmacologically and are linked to functional responses.
Transporter-mediated uptake
In simple terms: The serotonin transporter grabs serotonin from the synapse and pulls it back into the neuron, using ion gradients as an energy source.
SLC6A4 (serotonin transporter) binds serotonin and couples its translocation to sodium and chloride gradients. A potassium-binding site has been identified in SLC6A4 that is critical for the transport cycle, and its disruption affects substrate binding and translocation. Platelet plasma membrane serotonin transporter exhibits similar substrate and inhibitor binding properties, serving as a model for uptake studies.
Vesicular packaging
In simple terms: Inside the neuron, another transporter packs serotonin into tiny bubbles called vesicles for later release.
VMAT2 (SLC18A2) binds serotonin in the cytoplasm and transports it into synaptic vesicles using a proton gradient. Structural studies have revealed the transport and inhibition mechanisms of human VMAT2, including how it recognizes serotonin and other monoamines. This vesicular packaging is essential for regulated serotonin release.
Intracellular serotonin-binding proteins
In simple terms: Some proteins inside cells also bind serotonin, possibly to store or modulate its availability.
Soluble serotonin-binding proteins have been identified in bovine cerebral cortex, where they interact with serotonin and catecholamines. These proteins may regulate intracellular serotonin levels or participate in signaling, though their exact functions require further study.
Pathological serotonin binding
In simple terms: In some diseases, serotonin binding by immune cells or other tissues can drive harmful processes.
In ovarian cancer, serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk, indicating that serotonin binding in the tumor microenvironment can promote drug resistance. In addiction models, synaptic serotonin binding modulates the transition to cocaine addiction, highlighting behavioral consequences of altered serotonin binding.
Key Genes Involved in GO:0051378 serotonin binding
The following genes encode proteins that directly bind serotonin or are critically involved in serotonin binding-related processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC6A4 | Serotonin transporter; binds serotonin for reuptake | Target of SSRIs; ion-coupled transport; potassium-binding site [2,6] |
| SLC18A2 | Vesicular monoamine transporter 2 (VMAT2); binds serotonin for vesicular packaging | Structural and pharmacological studies; monoamine storage |
| HTR1A | Serotonin receptor 1A; binds serotonin | Mood, anxiety, and antidepressant response |
| HTR2A | Serotonin receptor 2A; binds serotonin | Psychosis, psychedelic drug action [3,4] |
| HTR2C | Serotonin receptor 2C; binds serotonin | Appetite, mood regulation |
| HTR3A | Serotonin receptor 3A; ligand-gated ion channel | Nausea, emesis, IBS |
| HTR4 | Serotonin receptor 4; binds serotonin | Gut motility, memory |
| HTR6 | Serotonin receptor 6; binds serotonin | Cognitive function |
| HTR7 | Serotonin receptor 7; binds serotonin | Circadian rhythm, mood |
| TPH1 | Tryptophan hydroxylase 1; synthesizes serotonin in periphery | Serotonin biosynthesis |
| TPH2 | Tryptophan hydroxylase 2; synthesizes serotonin in brain | Central serotonin synthesis |
| SLC6A4 variants | Polymorphic transporter; alters serotonin binding | Genetic association with psychiatric traits |
| MAOA | Monoamine oxidase A; degrades serotonin | Serotonin catabolism; aggression |
| MAOB | Monoamine oxidase B; degrades serotonin | Neurodegeneration |
| SERT (SLC6A4) accessory proteins | Modulate transporter trafficking and binding | Regulation of serotonergic tone |
| Serotonin-binding proteins (soluble) | Bind serotonin and catecholamines | Cortical monoamine homeostasis |
How Is serotonin binding Regulated?
Serotonin binding is regulated at multiple levels. The serotonin transporter SLC6A4 requires sodium and chloride for substrate binding and is modulated by a potassium-binding site that influences the transport cycle [2,6]. Receptor binding affinity can be regulated by post-translational modifications and allosteric modulators. In disease contexts, serotonin binding in macrophages is linked to metabolic crosstalk that promotes chemoresistance. Synaptic serotonin binding is dynamically regulated during cocaine addiction, affecting behavioral transitions.
serotonin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A4 | Depression, anxiety, SSRI response | Knockout and point-mutation models in neurons [2,6] |
| SLC18A2 | Monoamine storage disorders | Knock-in of VMAT2 mutations; vesicular transport assays |
| HTR2A | Psychosis, psychedelic response | Overexpression and knockout in cortical neurons [3,4] |
| Macrophage serotonin binding | Ovarian cancer chemoresistance | Co-culture with macrophages; knockout of serotonin-binding proteins |
| Serotonin-binding proteins | Cortical monoamine regulation | Knockout in animal models; binding assays |
Neuropsychiatric disorders
Alterations in serotonin binding by receptors and the transporter SLC6A4 are implicated in depression, anxiety, and schizophrenia. The 5-HT2 receptor binding sites have functional correlates in neuropharmacology. Genetic variants in SLC6A4 affect serotonin binding and are studied in mood disorders.
Addiction
Synaptic serotonin binding modulates the transition to cocaine addiction, as shown in animal models where serotonin release and receptor binding influence drug-seeking behavior. This highlights serotonin binding as a target for addiction research.
Cancer
In ovarian cancer, serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk, indicating that serotonin binding in immune cells can promote tumor survival. This suggests serotonin binding proteins as potential therapeutic targets in oncology.
Monoamine-related conditions
VMAT2 (SLC18A2) binds serotonin for vesicular storage, and its dysfunction is associated with monoamine disorders. Soluble serotonin-binding proteins in the cortex may also contribute to monoamine homeostasis.
From serotonin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC6A4 potassium-binding site regulate serotonin transport? | Point mutation knock-in of SLC6A4 in cell lines |
| What is the role of VMAT2 in serotonin packaging? | Knockout of SLC18A2 in neuronal cells |
| How does serotonin binding in macrophages affect chemoresistance? | Knockout of serotonin-binding proteins in macrophages co-cultured with ovarian cancer cells |
| Does HTR2A overexpression alter serotonin signaling? | Overexpression of HTR2A in heterologous cells or neurons [3,4] |
| What is the impact of serotonin binding on cocaine addiction? | Knockout of serotonin receptors in reward circuitry |
| Can soluble serotonin-binding proteins modulate monoamine levels? | Tagged knock-in for localization and binding assays |
How to Study the serotonin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and density of serotonin-binding sites | Receptor and transporter characterization [3,6] |
| Uptake assays | Serotonin transport activity | SLC6A4 and VMAT2 function [6,7] |
| Cryo-EM | 3D structure of serotonin-binding proteins | Ion sites and inhibitor binding [2,7] |
| Mutagenesis | Role of specific residues in serotonin binding | Potassium-binding site in SLC6A4 |
| Knockout models | Loss-of-function effects on serotonin binding | Behavioral and disease studies [1,5] |
| Overexpression | Gain-of-function effects | Receptor signaling |
| Co-culture assays | Cell-cell interactions via serotonin | Macrophage-cancer chemoresistance |
| Behavioral assays | Addiction and mood-related outcomes | Cocaine addiction models |
Binding assays
Radioligand binding assays using tritiated serotonin or selective ligands measure affinity and density of serotonin-binding sites in membranes or cells [3,6]. These assays are foundational for characterizing receptors and transporters.
Transport assays
Uptake assays with radiolabeled serotonin in cells expressing SLC6A4 or VMAT2 measure transport activity and the effects of ions or inhibitors [6,7]. Such assays can be combined with electrophysiology to resolve conformational changes.
Structural biology
Cryo-EM and X-ray crystallography have resolved structures of SLC6A4 and VMAT2, revealing serotonin-binding pockets and ion sites [2,7]. These methods guide mutagenesis and drug design.
Genetic and pharmacological models
Knockout, knock-in, and overexpression models in cells and animals allow causal testing of serotonin-binding proteins in behavior and disease [1,5]. Pharmacological inhibitors further validate targets.
How CRISPR Can Be Used to Study GO:0051378 serotonin binding
Knockout
CRISPR knockout of genes encoding serotonin-binding proteins, such as SLC6A4 or HTR2A, enables loss-of-function studies to determine their roles in serotonin uptake, signaling, and behavior [2,4]. Knockout models can be used in cell lines or primary neurons to assess downstream effects.
Point Mutation
Point mutations can be introduced into serotonin-binding proteins to test the function of specific residues, such as the potassium-binding site in SLC6A4. This approach helps dissect ion coupling and substrate recognition.
Knock-in
Knock-in of disease-associated variants or tagged versions of serotonin-binding proteins allows tracking of localization and function in vivo [7,8]. For example, tagging VMAT2 can reveal vesicular trafficking.
Overexpression
Overexpression of serotonin receptors or transporters in heterologous cells or neurons can amplify signaling and binding for biochemical assays [3,4]. This is useful for studying receptor pharmacology and drug responses.
How EDITGENE Supports serotonin binding Research
Researchers studying serotonin binding-related genes often need to determine whether a candidate gene is causally involved in serotonin binding, transport, or downstream signaling. EDITGENE provides CRISPR-based services to create precise genetic models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for serotonin binding research.
Frequently Asked Questions About serotonin binding
What is serotonin binding?
Serotonin binding (GO:0051378) is the molecular function of selectively interacting with serotonin (5-hydroxytryptamine), a monoamine neurotransmitter with hormonal properties, as defined by the Gene Ontology.
What genes are involved in serotonin binding?
Key genes include SLC6A4 (serotonin transporter), SLC18A2 (VMAT2), and serotonin receptors HTR1-7, as well as soluble serotonin-binding proteins [2,4,6,7,8].
What is the role of SLC6A4 in serotonin binding?
SLC6A4 binds serotonin for reuptake into neurons, coupling substrate binding to sodium and chloride gradients, and is modulated by a potassium-binding site [2,6].
How does VMAT2 bind serotonin?
VMAT2 (SLC18A2) binds serotonin in the cytoplasm and transports it into synaptic vesicles using a proton gradient, as revealed by structural studies.
Which diseases are linked to serotonin binding?
Serotonin binding is implicated in neuropsychiatric disorders, addiction, and cancer chemoresistance, among others [1,3,4,5].
How can CRISPR be used to study serotonin binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of serotonin-binding proteins in cells and animals [2,7].
What methods measure serotonin binding?
Radioligand binding assays, uptake assays, cryo-EM, and mutagenesis are commonly used to measure and characterize serotonin binding [2,3,6,7].
Is serotonin binding involved in addiction?
Yes, synaptic serotonin binding modulates the transition to cocaine addiction in animal models.
What are soluble serotonin-binding proteins?
These are proteins in the cerebral cortex that bind serotonin and catecholamines, potentially regulating monoamine homeostasis.
Why is serotonin binding important for drug development?
Many drugs target serotonin receptors and transporters, and understanding their binding mechanisms aids in designing better therapeutics [3,4].
Conclusion
Serotonin binding (GO:0051378) is a fundamental molecular function that underlies serotonergic neurotransmission and is mediated by diverse proteins including receptors, transporters, and soluble binding proteins. Its dysregulation is linked to psychiatric disorders, addiction, and cancer, making it a critical area of research. Advances in structural biology and CRISPR-based models continue to elucidate the mechanisms and therapeutic potential of serotonin binding.
References
- 1. Li J et al.. 2026. Serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk in ovarian cancer.. Cell Metab 38(2):331-349.e10 PMID: 41412121
- 2. Hellsberg E et al.. 2024. Identification of the potassium-binding site in serotonin transporter.. Proc Natl Acad Sci U S A 121(18):e2319384121 PMID: 38652746
- 3. Leysen JE et al.. 1984. Serotonin-S2 receptor binding sites and functional correlates.. Neuropharmacology 23(12B):1493-501 PMID: 6396526
- 4. Nichols DE et al.. 2008. Serotonin receptors.. Chem Rev 108(5):1614-41 PMID: 18476671
- 5. Li Y et al.. 2021. Synaptic mechanism underlying serotonin modulation of transition to cocaine addiction.. Science 373(6560):1252-1256 PMID: 34516792
- 6. Humphreys CJ et al.. 1991. Substrate and inhibitor binding and translocation by the platelet plasma membrane serotonin transporter.. Biochem Soc Trans 19(1):95-8 PMID: 2037207
- 7. Wu D et al.. 2024. Transport and inhibition mechanisms of human VMAT2.. Nature 626(7998):427-434 PMID: 38081299
- 8. Jimenez Del Rio M et al.. 1992. Serotonin-binding proteins in the bovine cerebral cortex: interaction with serotonin and catecholamines.. Eur J Pharmacol 225(3):225-34 PMID: 1516655
